APOTEX CORP. for APOTEX CORP.
What was lobbied
2 issue areas, each in the filer's own words, with who lobbied on it and where.
Trade (domestic/foreign) TRD
Federal policy related to the inclusion of provisions that enhance and facilitate generic drug and biosimilar competition in the United States Mexico Canada Trade Agreement.
Foreign entity interest: Aposherm Delaware Holdings Corporation, Aposherm Inc., Apotex Holdings Inc., Sherfam Inc., and Shermco Inc., the parent companies of Apotex Corp. identified on LD-1, have direct or indirect interests in companies that develop, manufacture, and/or sell generic drugs and therefore are interested in the issues identified in this report.
| Lobbyist | Covered position, as disclosed |
|---|---|
| STEVEN GIULI | — |
Pharmacy PHA
S. 974/HR2212, the Creating and Restoring Equal Access to Equivalent Samples Act of 2017, provisions relating to the provision of brand drug products by brand manufacturers to generic manufacturers for development testing, and for shared Risk Evaluation and Mitigation (REMS) programs for brand and generic pharmaceuticals; S. 2476, the Expanding Access to Low Cost Generics Act, provisions relating to pharmaceutical market blockages caused by "parked" Hatch-Waxman 180-day exclusivity periods; Federal policy relating to pharmaceutical market blockages caused by parked Hatch-Waxman 180-day exclusivity periods; Federal policy relating to generic pharmaceutical drug prices; Public Law 115-52, the FDA Reauthorization Act of 2017, Section 808, Incentivizing Generic Drug Developments, provisions relating to exclusivity for competitive generic therapies; and Federal policy relating to FDA proposed rule Electronic Distribution of Prescribing Information for Human Prescription Drugs, Including Biological Products, Docket No. FDA-2007-N-0363, RIN 0910-AG18
Foreign entity interest: Aposherm Delaware Holdings Corporation, Aposherm Inc., Apotex Holdings Inc., Sherfam Inc., and Shermco Inc., the parent companies of Apotex Corp. identified on LD-1, have direct or indirect interests in companies that develop, manufacture, and/or sell generic drugs and therefore are interested in the issues identified in this report.
| Lobbyist | Covered position, as disclosed |
|---|---|
| STEVEN GIULI | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.